Keynote Lecture
WEB Radiolabeled magnetic nanoparticles for cancer theranostics
Wednesday (01.01.2020) 00:00 - 00:30 Part of:Nano-scaled magnetic particles hold great potential in biomedical applications owing to their favorable properties such as ease of synthesis, biocompatibility, and biodegradability 1. The objective of the study was to prepare 131I-labeled magnetic nanoparticles and to investigate their suitability for combined radionuclide-hyperthermia treatment of cancer cells. Magnetic nanoparticles (MNPs) were prepared as a ~40 nm flower-like forms, with exceptionally strong heating under oscillating magnetic field. Their biocompatibility was improved by coating with 3-aminopropyltriethoxysilane (APTES). APTES-MNPs coupled to the previously 131I-labeled antibody (CC49). The therapeutic effect was investigated after intratumoral injection of 131I-CC49-APTES-MNPs complex in LS174T human colon adenocarcinoma xenografts on NOD-SCID mice. The studies revealed the complex retention in the tumor on day 14th. Combined radionuclide-hyperthermia therapy showed significant (P<0.01) suppression of the tumor growth when compared to the control groups and better effect than radionuclide therapy or hyperthermia treatment alone. Histopathology analysis proved the necrosis and apoptosis in treated tumors without general toxicity observed as judging by the animals’ body mass. Promising results obtained for combined radionuclide-hyperthermia cancer therapy induced by 131I-CC49-APTES-MNPs complex, support the idea that combined effect can be superior over individual treatment. The same radiolabeled complex may be used with low activities for diagnostic purposes.
